Sharon Shacham
Direktor/Vorstandsmitglied bei ACRIVON THERAPEUTICS, INC.
Vermögen: 165 800 $ am 30.04.2024
Profil
Sharon Shacham is the founder of Karyopharm Therapeutics, Inc., which was founded in 2008.
She held the title of President & Chief Scientific Officer from 2015 to 2021.
Dr. Shacham is also currently working as an Independent Director at Acrivon Therapeutics, Inc. since 2020.
In her former positions, Dr. Shacham worked as a Director of Algorithm & Software Development at Predix Pharmaceuticals, Inc. She also served as the Senior Vice President of Drug Development at EPIX Pharmaceuticals, Inc. from 2000 to 2009.
Dr. Shacham's education includes undergraduate, MBA, and doctorate degrees from Tel-Aviv University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.04.2024 | 19 575 ( 0,06% ) | 165 800 $ | 30.04.2024 |
Aktive Positionen von Sharon Shacham
| Unternehmen | Position | Beginn |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.10.2020 |
Ehemalige bekannte Positionen von Sharon Shacham
| Unternehmen | Position | Ende |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Gründer | 03.05.2021 |
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Corporate Officer/Principal | 01.04.2009 |
Predix Pharmaceuticals, Inc.
 Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | Corporate Officer/Principal | - |
Ausbildung von Sharon Shacham
| Tel-Aviv University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
EPIX Pharmaceuticals, Inc.
EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
Predix Pharmaceuticals, Inc.
Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | Health Technology |
| Acrivon Therapeutics, Inc. |
